für die Schweiz
Biocomposites announces new CE Mark for STIMULAN®
First calcium matrix to receive European approval as an antibiotic carrier for use in bone and soft tissue
Keele, UK, April 23 2020 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announced that its STIMULAN products have gained a new European CE mark approval for mixing with antibiotics: vancomycin, gentamicin and tobramycin, for use in infected bone and soft tissue.
STIMULAN® targets high concentrations of antibiotic at the point of infection at levels unachievable systemically – which lowers rates of reinfection, saves costs and improves patient outcomes. The STIMULAN® Rapid Cure and STIMULAN® Kit products are the first and only calcium matrices that can carry an antibiotic into bone and soft tissue; offering surgeons the flexibility to apply a broad spectrum of ‘off-the-shelf’ antibiotics at concentrations that will support their patient-specific treatment plans.
STIMULAN® is already used in over 50,000 cases every year and in thousands of hospitals around the world.